|
|
(One intermediate revision not shown.) |
Line 1: |
Line 1: |
| | | |
| ==Solution structure of de novo macrocycle design8.2== | | ==Solution structure of de novo macrocycle design8.2== |
- | <StructureSection load='6ben' size='340' side='right'caption='[[6ben]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | + | <StructureSection load='6ben' size='340' side='right'caption='[[6ben]]' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[6ben]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BEN OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6BEN FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6ben]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BEN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6BEN FirstGlance]. <br> |
- | </td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DAR:D-ARGININE'>DAR</scene>, <scene name='pdbligand=DGL:D-GLUTAMIC+ACID'>DGL</scene>, <scene name='pdbligand=DGN:D-GLUTAMINE'>DGN</scene>, <scene name='pdbligand=DPR:D-PROLINE'>DPR</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR, 20 models</td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ben FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ben OCA], [http://pdbe.org/6ben PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ben RCSB], [http://www.ebi.ac.uk/pdbsum/6ben PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ben ProSAT]</span></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DAR:D-ARGININE'>DAR</scene>, <scene name='pdbligand=DGL:D-GLUTAMIC+ACID'>DGL</scene>, <scene name='pdbligand=DGN:D-GLUTAMINE'>DGN</scene>, <scene name='pdbligand=DPR:D-PROLINE'>DPR</scene></td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ben FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ben OCA], [https://pdbe.org/6ben PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ben RCSB], [https://www.ebi.ac.uk/pdbsum/6ben PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ben ProSAT]</span></td></tr> |
| </table> | | </table> |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
Line 20: |
Line 21: |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
| + | [[Category: Homo sapiens]] |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Baker, B]] | + | [[Category: Baker B]] |
- | [[Category: Hosseinzadeh, P]] | + | [[Category: Hosseinzadeh P]] |
- | [[Category: Pardo-Avila, F]] | + | [[Category: Pardo-Avila F]] |
- | [[Category: Shortridge, M D]] | + | [[Category: Shortridge MD]] |
- | [[Category: Varani, G]] | + | [[Category: Varani G]] |
- | [[Category: De novo]]
| + | |
- | [[Category: De novo protein]]
| + | |
- | [[Category: Macrocycle]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Mixed-chirality peptide macrocycles such as cyclosporine are among the most potent therapeutics identified to date, but there is currently no way to systematically search the structural space spanned by such compounds. Natural proteins do not provide a useful guide: Peptide macrocycles lack regular secondary structures and hydrophobic cores, and can contain local structures not accessible with l-amino acids. Here, we enumerate the stable structures that can be adopted by macrocyclic peptides composed of l- and d-amino acids by near-exhaustive backbone sampling followed by sequence design and energy landscape calculations. We identify more than 200 designs predicted to fold into single stable structures, many times more than the number of currently available unbound peptide macrocycle structures. Nuclear magnetic resonance structures of 9 of 12 designed 7- to 10-residue macrocycles, and three 11- to 14-residue bicyclic designs, are close to the computational models. Our results provide a nearly complete coverage of the rich space of structures possible for short peptide macrocycles and vastly increase the available starting scaffolds for both rational drug design and library selection methods.
Comprehensive computational design of ordered peptide macrocycles.,Hosseinzadeh P, Bhardwaj G, Mulligan VK, Shortridge MD, Craven TW, Pardo-Avila F, Rettie SA, Kim DE, Silva DA, Ibrahim YM, Webb IK, Cort JR, Adkins JN, Varani G, Baker D Science. 2017 Dec 15;358(6369):1461-1466. doi: 10.1126/science.aap7577. PMID:29242347[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Hosseinzadeh P, Bhardwaj G, Mulligan VK, Shortridge MD, Craven TW, Pardo-Avila F, Rettie SA, Kim DE, Silva DA, Ibrahim YM, Webb IK, Cort JR, Adkins JN, Varani G, Baker D. Comprehensive computational design of ordered peptide macrocycles. Science. 2017 Dec 15;358(6369):1461-1466. doi: 10.1126/science.aap7577. PMID:29242347 doi:http://dx.doi.org/10.1126/science.aap7577
|